Journal Mobile Options
Table of Contents
Vol. 22, No. 2, 2003
Issue release date: March–April 2003
Free Access
Neuroepidemiology 2003;22:124–129
(DOI:10.1159/000068745)

Vestibular Schwannoma, Tinnitus and Cellular Telephones

Hardell L.a,c · Hansson Mild K.c,d · Sandström M.d · Carlberg M.a · Hallquist A.e · Påhlson A.b
aDepartment of Oncology, and bDepartment of Neurology, University Hospital, Örebro, cDepartment of Natural Sciences, Örebro University, Örebro, dNational Institute for Working Life, Umeå, and eDepartment of Oncology/Pathology, Karolinska Institute, Radiumhemmet, Stockholm, Sweden
email Corresponding Author

Abstract

Cases with tinnitus after using analogue cellular telephones are presented. An increased odds ratio of 3.45, 95% confidence interval (CI) 1.77–6.76, was found for vestibular schwannoma (VS) associated with the use of analogue cell phones. During the time period 1960–1998, the age-standardized incidence of VS in Sweden significantly increased yearly by +2.53% (CI 1.71–3.35). A significant increase in the incidence of VS was only found for the latter of the two time periods 1960–1979 and 1980–1998. For all other brain tumors taken together, the incidence significantly increased yearly by +0.80% (CI 0.59–1.02) for the time period 1960–1998, although the increase was only significant for benign tumors other than VS during 1960–1979.


 goto top of outline Key Words

  • Acoustic neurinoma
  • Incidence
  • Cellular telephones

 goto top of outline Abstract

Cases with tinnitus after using analogue cellular telephones are presented. An increased odds ratio of 3.45, 95% confidence interval (CI) 1.77–6.76, was found for vestibular schwannoma (VS) associated with the use of analogue cell phones. During the time period 1960–1998, the age-standardized incidence of VS in Sweden significantly increased yearly by +2.53% (CI 1.71–3.35). A significant increase in the incidence of VS was only found for the latter of the two time periods 1960–1979 and 1980–1998. For all other brain tumors taken together, the incidence significantly increased yearly by +0.80% (CI 0.59–1.02) for the time period 1960–1998, although the increase was only significant for benign tumors other than VS during 1960–1979.

Copyright © 2003 S. Karger AG, Basel


 goto top of outline References
  1. Casadei GP, Komori T, Scheithauer BW, Miller GM, Parisi JE, Kelly PJ: Intracranial parenchymal schwannoma. A clinicopathological and neuroimaging study of nine cases. J Neurosurg 1993;79:217–222.
  2. Baguley DM, Chang P, Moffat DA: Tinnitus and vestibular schwannoma. Semin Hear 2001;22:77–87.

    External Resources

  3. Brackman DE, Syms CA: Tumors of the auditory-vestibular nerve; in Ludman H, Wright T (eds): Diseases of the Ear, ed 6. London, Arnold, 1998, pp 533–547.
  4. Moffat DA, Hardy DG, Irving RM, Viani L, Beynon GI, Baguley DM: Referral patterns in vestibular schwannomas. Clin Otolaryngol 1995;20:80–83.
  5. Tos M, Charabi S, Thomsen J: Incidence of vestibular schwannomas. Laryngoscope 1999;109:736–740.
  6. Charabi S, Thomsen J, Tos M, Charabi B, Mantoni M, Borgesen SE: Acoustic neuroma/vestibular schwannoma growth: Past, present and future. Acta Otolaryngol 1998;118:327–332.
  7. Walsh RM, Bath AP, Bance ML, Keller A, Tator CH, Rutka JA: The role of conservative management of vestibular schwannoma. Clin Otolaryngol 2000;25:28–39.
  8. Moffat DA, Baguley DM, Beynon GJ, Da Cruz M: Clinical acumen and vestibular schwannoma. Am J Otol 1998;19:82–87.
  9. Kentala E, Pykko I: Clinical picture of vestibular schwannoma. Auris Nasus Larynx 2001;28:15–22.
  10. Bikhazi NB, Slattery WH 3rd, Lalwani AK, Jackler RK, Bikhazi PH, Brackman DE: Familial occurrence of unilateral vestibular schwannoma. Laryngoscope 1997;107:1176–1180.
  11. Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH: Incidence of vestibular schwannoma in Denmark, 1977–1995. Am J Otology 2000;21:690–694.
  12. Oftedal G, Wilén J, Sandström M, Hansson Mild K: Symptoms experienced in connection with mobile phone use. Occup Med (Lond) 2000;50:237–245.
  13. Sandström M, Wilén J, Oftedal G, Hansson Mild K: Mobile phone use and subjective symptoms. Comparison of symptoms experienced by users of analogue and digital mobile phones. Occup Med (Lond) 2001;51:25–35.
  14. Hardell L, Hallquist A, Hansson Mild K, Carlberg M, Påhlson A, Lilja A: Cellular and cordless telephones and the risk for brain tumours. Eur J Cancer Prev 2002;11:377–386.
  15. Cancer Incidence in Five Continents. Lyon, IARC, 1997, vol 4.
  16. Dawes PJD, Basiouny HE: Outcome of using magnetic resonance imaging as an initial screen to exclude vestibular schwannoma in patients presenting with unilateral tinnitus. J Laryngol Otol 1999;113:818–822.
  17. Martens L: Electromagnetic field calculations for wireless telephones. Radio Serv Bull 1994;27:9–11.
  18. Kellényi L, Thuróczy G, Faludy B, Lénárd L: Effects of mobile GSM radiotelephone exposure on the auditory brainstem response (ABR). Neurobiology 1999;7:79–81.
  19. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG: Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro-oncol 2001;141–151.
  20. Desmeules M, Mikkelsen T, Mao Y: Increasing incidence of primary malignant brain tumors: Influence of diagnostic methods. J Natl Cancer Inst 1992;84:442–445.
  21. The National Board of Health and Welfare 1993. Stockholm, Sweden, 1999.

 goto top of outline Author Contacts

Dr. Lennart Hardell
Department of Oncology, University Hospital
S–701 85 Örebro (Sweden)
Tel. +46 19 602 10 00, Fax +46 19 10 17 68
E-Mail lennart.hardell@orebroll.se


 goto top of outline Article Information

Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 4, Number of References : 21


 goto top of outline Publication Details

Neuroepidemiology
Founded 1982 by B.S. Schoenberg, continued by M. Alter (1989–1996)

Vol. 22, No. 2, Year 2003 (Cover Date: March-April 2003)

Journal Editor: G.C. Román, San Antonio, Tex.
ISSN: 0251–5350 (print), 1423–0208 (Online)

For additional information: http://www.karger.com/journals/ned


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Cases with tinnitus after using analogue cellular telephones are presented. An increased odds ratio of 3.45, 95% confidence interval (CI) 1.77–6.76, was found for vestibular schwannoma (VS) associated with the use of analogue cell phones. During the time period 1960–1998, the age-standardized incidence of VS in Sweden significantly increased yearly by +2.53% (CI 1.71–3.35). A significant increase in the incidence of VS was only found for the latter of the two time periods 1960–1979 and 1980–1998. For all other brain tumors taken together, the incidence significantly increased yearly by +0.80% (CI 0.59–1.02) for the time period 1960–1998, although the increase was only significant for benign tumors other than VS during 1960–1979.



 goto top of outline Author Contacts

Dr. Lennart Hardell
Department of Oncology, University Hospital
S–701 85 Örebro (Sweden)
Tel. +46 19 602 10 00, Fax +46 19 10 17 68
E-Mail lennart.hardell@orebroll.se


 goto top of outline Article Information

Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 4, Number of References : 21


 goto top of outline Publication Details

Neuroepidemiology
Founded 1982 by B.S. Schoenberg, continued by M. Alter (1989–1996)

Vol. 22, No. 2, Year 2003 (Cover Date: March-April 2003)

Journal Editor: G.C. Román, San Antonio, Tex.
ISSN: 0251–5350 (print), 1423–0208 (Online)

For additional information: http://www.karger.com/journals/ned


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Casadei GP, Komori T, Scheithauer BW, Miller GM, Parisi JE, Kelly PJ: Intracranial parenchymal schwannoma. A clinicopathological and neuroimaging study of nine cases. J Neurosurg 1993;79:217–222.
  2. Baguley DM, Chang P, Moffat DA: Tinnitus and vestibular schwannoma. Semin Hear 2001;22:77–87.

    External Resources

  3. Brackman DE, Syms CA: Tumors of the auditory-vestibular nerve; in Ludman H, Wright T (eds): Diseases of the Ear, ed 6. London, Arnold, 1998, pp 533–547.
  4. Moffat DA, Hardy DG, Irving RM, Viani L, Beynon GI, Baguley DM: Referral patterns in vestibular schwannomas. Clin Otolaryngol 1995;20:80–83.
  5. Tos M, Charabi S, Thomsen J: Incidence of vestibular schwannomas. Laryngoscope 1999;109:736–740.
  6. Charabi S, Thomsen J, Tos M, Charabi B, Mantoni M, Borgesen SE: Acoustic neuroma/vestibular schwannoma growth: Past, present and future. Acta Otolaryngol 1998;118:327–332.
  7. Walsh RM, Bath AP, Bance ML, Keller A, Tator CH, Rutka JA: The role of conservative management of vestibular schwannoma. Clin Otolaryngol 2000;25:28–39.
  8. Moffat DA, Baguley DM, Beynon GJ, Da Cruz M: Clinical acumen and vestibular schwannoma. Am J Otol 1998;19:82–87.
  9. Kentala E, Pykko I: Clinical picture of vestibular schwannoma. Auris Nasus Larynx 2001;28:15–22.
  10. Bikhazi NB, Slattery WH 3rd, Lalwani AK, Jackler RK, Bikhazi PH, Brackman DE: Familial occurrence of unilateral vestibular schwannoma. Laryngoscope 1997;107:1176–1180.
  11. Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH: Incidence of vestibular schwannoma in Denmark, 1977–1995. Am J Otology 2000;21:690–694.
  12. Oftedal G, Wilén J, Sandström M, Hansson Mild K: Symptoms experienced in connection with mobile phone use. Occup Med (Lond) 2000;50:237–245.
  13. Sandström M, Wilén J, Oftedal G, Hansson Mild K: Mobile phone use and subjective symptoms. Comparison of symptoms experienced by users of analogue and digital mobile phones. Occup Med (Lond) 2001;51:25–35.
  14. Hardell L, Hallquist A, Hansson Mild K, Carlberg M, Påhlson A, Lilja A: Cellular and cordless telephones and the risk for brain tumours. Eur J Cancer Prev 2002;11:377–386.
  15. Cancer Incidence in Five Continents. Lyon, IARC, 1997, vol 4.
  16. Dawes PJD, Basiouny HE: Outcome of using magnetic resonance imaging as an initial screen to exclude vestibular schwannoma in patients presenting with unilateral tinnitus. J Laryngol Otol 1999;113:818–822.
  17. Martens L: Electromagnetic field calculations for wireless telephones. Radio Serv Bull 1994;27:9–11.
  18. Kellényi L, Thuróczy G, Faludy B, Lénárd L: Effects of mobile GSM radiotelephone exposure on the auditory brainstem response (ABR). Neurobiology 1999;7:79–81.
  19. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG: Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro-oncol 2001;141–151.
  20. Desmeules M, Mikkelsen T, Mao Y: Increasing incidence of primary malignant brain tumors: Influence of diagnostic methods. J Natl Cancer Inst 1992;84:442–445.
  21. The National Board of Health and Welfare 1993. Stockholm, Sweden, 1999.